264 related articles for article (PubMed ID: 18405946)
1. Feasibility and economic impact of a clinical pathway for pap test utilization in Gynecologic Oncology practice.
Santillan A; Govan L; Zahurak ML; Diaz-Montes TP; Giuntoli RL; Bristow RE
Gynecol Oncol; 2008 Jun; 109(3):388-93. PubMed ID: 18405946
[TBL] [Abstract][Full Text] [Related]
2. Improving quality and decreasing cost in gynecologic oncology care. Society of gynecologic oncology recommendations for clinical practice.
Rimel BJ; Burke WM; Higgins RV; Lee PS; Lutman CV; Parker L
Gynecol Oncol; 2015 May; 137(2):280-4. PubMed ID: 25735256
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillance.
Bristow RE; Purinton SC; Santillan A; Diaz-Montes TP; Gardner GJ; Giuntoli RL
Gynecol Oncol; 2006 Nov; 103(2):709-13. PubMed ID: 16797686
[TBL] [Abstract][Full Text] [Related]
4. Clinical and cost implications of new technologies for cervical cancer screening: the impact of test sensitivity.
Hutchinson ML; Berger BM; Farber FL
Am J Manag Care; 2000 Jul; 6(7):766-80. PubMed ID: 11067374
[TBL] [Abstract][Full Text] [Related]
5. Primary care physicians' awareness and adherence to cervical cancer screening guidelines in Texas.
Holland-Barkis P; Forjuoh SN; Couchman GR; Capen C; Rascoe TG; Reis MD
Prev Med; 2006 Feb; 42(2):140-5. PubMed ID: 16290022
[TBL] [Abstract][Full Text] [Related]
6. Optimum screening interventions for gynecologic malignancies.
Lea JS; Miller DS
Tex Med; 2001 Feb; 97(2):49-55. PubMed ID: 11233059
[TBL] [Abstract][Full Text] [Related]
7. Understanding the financial impact of covering new screening technologies. The case of automated Pap smears.
McQuarrie HG; Ogden J; Costa M
J Reprod Med; 2000 Nov; 45(11):898-906. PubMed ID: 11127101
[TBL] [Abstract][Full Text] [Related]
8. The implementation of critical pathways in gynecologic oncology in a managed care setting: a cost analysis.
Ghosh K; Downs LS; Padilla LA; Murray KP; Twiggs LB; Letourneau CM; Carson LF
Gynecol Oncol; 2001 Nov; 83(2):378-82. PubMed ID: 11606100
[TBL] [Abstract][Full Text] [Related]
9. Healthcare resource use and costs associated with cervical, vaginal and vulvar cancers in a large U.S. health plan.
Insinga RP; Ye X; Singhal PK; Carides GW
Gynecol Oncol; 2008 Nov; 111(2):188-96. PubMed ID: 18757080
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analyses in gynecologic oncology: methodological quality and trends.
Manuel MR; Chen LM; Caughey AB; Subak LL
Gynecol Oncol; 2004 Apr; 93(1):1-8. PubMed ID: 15047206
[TBL] [Abstract][Full Text] [Related]
11. Incorporating laparoscopy in the practice of a gynecologic oncology service: actual impact beyond clinical trials data.
Ghezzi F; Cromi A; Uccella S; Siesto G; Zefiro F; Bolis P
Ann Surg Oncol; 2009 Aug; 16(8):2305-14. PubMed ID: 19459012
[TBL] [Abstract][Full Text] [Related]
12. Routine vaginal Pap test is not useful in women status-post hysterectomy for benign disease.
Farghaly H; Bourgeois D; Houser PM; Padmanabhan V; Lage JM; Hoda RS
Diagn Cytopathol; 2006 Sep; 34(9):640-3. PubMed ID: 16900480
[TBL] [Abstract][Full Text] [Related]
13. Deviation-based cost modeling: a novel model to evaluate the clinical and economic impact of clinical pathways.
Vanounou T; Pratt W; Fischer JE; Vollmer CM; Callery MP
J Am Coll Surg; 2007 Apr; 204(4):570-9. PubMed ID: 17382215
[TBL] [Abstract][Full Text] [Related]
14. Prevention of cervical cancer with screening programme in Branicevo District and cost-effectiveness analysis adjusted to the territory of the Republic of Serbia.
Perovic S
J BUON; 2009; 14(1):93-6. PubMed ID: 19373953
[TBL] [Abstract][Full Text] [Related]
15. Screening for chlamydia with the Pap test.
Toyne H; Glasgow N; McGuiness C; Bowden FJ; Currie MJ
Aust Fam Physician; 2006 Sep; 35(9):743-4. PubMed ID: 16969449
[TBL] [Abstract][Full Text] [Related]
16. [Cost effectiveness of human papilloma virus testing in cervical cancer screening: a literature review].
Mejía A; Salas W
Biomedica; 2008 Mar; 28(1):160-72. PubMed ID: 18645671
[TBL] [Abstract][Full Text] [Related]
17. Cervical cancer screening in medically underserved California Latina and non-Latina women: effect of age and regularity of Pap testing.
Howell LP; Gurusinghe S; Tabnak F; Sciortino S
Cancer Detect Prev; 2009; 32(5-6):372-9. PubMed ID: 19264426
[TBL] [Abstract][Full Text] [Related]
18. Integrating human papillomavirus vaccination in cervical cancer control programmes.
Franco EL; Coutlée F; Ferenczy A
Public Health Genomics; 2009; 12(5-6):352-61. PubMed ID: 19684447
[TBL] [Abstract][Full Text] [Related]
19. Cervical screening in general practice - strategies for improving participation.
Byrnes P; McGoldrick C; Crawford M; Peers M
Aust Fam Physician; 2007 Mar; 36(3):183-4, 192. PubMed ID: 17339987
[TBL] [Abstract][Full Text] [Related]
20. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden.
Andrae B; Kemetli L; Sparén P; Silfverdal L; Strander B; Ryd W; Dillner J; Törnberg S
J Natl Cancer Inst; 2008 May; 100(9):622-9. PubMed ID: 18445828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
